Concepedia
Statistics
Publications
48
Citations
2K
H-Index
27
Active since
1998
Affiliations
Cubist Pharmaceuticals (United States)(Current)
The Wistar Institute
University of Pennsylvania
ALS Biopharma (United States)
The University of Texas MD Anderson Cancer Center
Joel Cassel is an author at Cubist Pharmaceuticals (United States) specializing in medicine, pharmacology, and drug discovery.
Top concepts
MedicinePharmacologyDrug DiscoveryPharmacotherapyBiochemistryNeuropharmacologyMolecular PharmacologyCell BiologyImmunologyNatural Sciences
Publications per year
1998–2024
Loperamide (ADL 2-1294), an Opioid Antihyperalgesic Agent with Peripheral Selectivity
Diane L. DeHaven‐Hudkins, Luz Cortes Burgos, Joel Cassel et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 145 citations
Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth
Troy E. Messick, Garry R. Smith, Samantha S. Soldan et al. · Science Translational Medicine · 2019 · 117 citations · Full text
Fragile X protein mitigates TDP-43 toxicity by remodeling RNA granules and restoring translation
Alyssa N. Coyne, Shizuka Yamada, Bhavani B. Siddegowda et al. · Human Molecular Genetics · 2015 · 95 citations · Full text
Genetics, Molecular Biology, Tdp-43 Toxicity +17
Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao et al. · Cancer Discovery · 2023 · 93 citations · Full text
Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth
Katelyn D. Miller, Katherine Pniewski, Caroline Perry et al. · Cancer Research · 2021 · 91 citations · Full text
1–5 of 48